Comparison of subretinal aflibercept vs ranibizumab vs bevacizumab in the context of PPV, pneumatic displacement with subretinal air and subretinal tPA in naive submacular haemorrhage secondary to nAMD. "The Submarine Study".

ABSTRACT:

Objective

To compare efficacy and safety profile of subretinal aflibercept, ranibizumab, and bevacizumab in the context of pars plana vitrectomy, pneumatic displacement with subretinal air and subretinal tPA for subretinal macular haemorrhage (SMH) due to naïve neovascular age-related macular degeneration (nAMD).

Design

Retrospective interventional cohort study.

Participants

123 eyes of 123 patients treated with subretinal aflibercept (n = 41, 33%), ranibizumab (n = 41,33%), and bevacizumab (n = 41, 33%).

Methods

Review of electronic medical records for best corrected visual acuity (BCVA), central subfoveal thickness (CST), and intraocular pressure (IOP) at baseline and 24 months after treatment.

Main outcome measures

BCVA, CST, and number of intravitrea

SUBMITTER: Iglicki M 

PROVIDER: S-EPMC10810790 | biostudies-literature | 2024 Feb

REPOSITORIES: biostudies-literature